[{"indications": "Indications\u00a0raised intra-ocular pressure in ocular hypertension, open-angle glaucoma,\r\npseudo-exfoliative glaucoma either as adjunct to\r\nbeta-blocker or used alone in patients unresponsive\r\nto beta-blockers or if beta-blockers contra-indicated", "name": "DORZOLAMIDE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "11 Eye", "11.6 Treatment of glaucoma", "Carbonic anhydrase inhibitors and systemic drugs", "DORZOLAMIDE"], "cautions": "Cautions\u00a0systemic absorption follows topical application; history of renal calculi; chronic corneal defects, history of intra-ocular\r\nsurgery; interactions: Appendix 1 (dorzolamide)", "side-effects": "Side-effects\u00a0\n(From Carbonic anhydrase inhibitors and systemic drugs: British National Formulary)\nCarbonic anhydrase inhibitors and systemic drugs; also nausea,\r\nbitter taste, dry mouth; headache, asthenia; ocular irritation, blurred\r\nvision, lacrimation, conjunctivitis, superficial punctuate keratitis,\r\neyelid inflammation; less commonly iridocyclitis; rarely hypersensitivity reactions (including urticaria,\r\nangioedema, bronchospasm), dizziness, paraesthesia, urolithiasis,\r\neyelid crusting, transient myopia, corneal oedema, epistaxis, throat\r\nirritation", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/213678.htm", "doses": ["Used alone, apply 3 times daily", "With topical beta-blocker, apply twice daily"], "pregnancy": "Pregnancy\u00a0manufacturer advises avoid\u2014toxicity in animal studies"}, {"indications": "Indications\u00a0raised intra-ocular pressure in ocular hypertension, open-angle glaucoma,\r\npseudo-exfoliative glaucoma either as adjunct to\r\nbeta-blocker or used alone in patients unresponsive\r\nto beta-blockers or if beta-blockers contra-indicated", "name": "DORZOLAMIDE With timolol", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "11 Eye", "11.6 Treatment of glaucoma", "Carbonic anhydrase inhibitors and systemic drugs", "DORZOLAMIDE", "With timolol"], "cautions": "Cautions\u00a0systemic absorption follows topical application; history of renal calculi; chronic corneal defects, history of intra-ocular\r\nsurgery; interactions: Appendix 1 (dorzolamide)", "side-effects": "Side-effects\u00a0\n(From Carbonic anhydrase inhibitors and systemic drugs: British National Formulary)\nCarbonic anhydrase inhibitors and systemic drugs; also nausea,\r\nbitter taste, dry mouth; headache, asthenia; ocular irritation, blurred\r\nvision, lacrimation, conjunctivitis, superficial punctuate keratitis,\r\neyelid inflammation; less commonly iridocyclitis; rarely hypersensitivity reactions (including urticaria,\r\nangioedema, bronchospasm), dizziness, paraesthesia, urolithiasis,\r\neyelid crusting, transient myopia, corneal oedema, epistaxis, throat\r\nirritation", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/73179.htm", "doses": ["Used alone, apply 3 times daily", "With topical beta-blocker, apply twice daily", "Name[Cosopt\u00ae (MSD) ] Ophthalmic solution (= eye drops),\r\nin Ocumeter\u00ae Plus metered-dose unit, dorzolamide (as hydrochloride)\r\n2%, timolol (as maleate) 0.5%, net price 5\u00a0mL = \u00a310.05Excipients  include benzalkonium chloride\nUnit dose eye drops, dorzolamide\r\n(as hydrochloride) 2%, timolol (as maleate) 0.5%, net price 60 \u00d7 0.2\u00a0mL\r\n= \u00a328.59"], "pregnancy": "Pregnancy\u00a0manufacturer advises avoid\u2014toxicity in animal studies"}]